Targeting cancer-specific glycoforms as demonstrated in recent times with highly specific antibodies of cancer-specific LYPD3,46 MUC1,49 and CD4350 glycoforms is a promising therapeutic strategy to selective cancer cells but not normal tissues. This evidence concerns the gene MUC1 and cancer.